Interaction between pathogenic proteins in neurodegenerative disorders

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 6, 2012, Pages 1166-1183

  Jellinger, Kurt A ^a  

^a INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

Author keywords

Aggregation; Interaction; Neurodegeneration; Oligomers; Pathogenic factors; Protein misfolding; Spreading

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL; ARTICLE; DEGENERATIVE DISEASE; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PRION DISEASE; PROTEOSTASIS DEFICIENCY;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; HUMANS; NEURODEGENERATIVE DISEASES; PRION DISEASES; PROTEOSTASIS DEFICIENCIES; TAU PROTEINS;

EID: 84861378458     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01507.x     Document Type: Article

References (313)

1. Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer's disease and other neurodegenerative disorders. Ann Neurol. 2011; 70: 532-40.
2. Golde TE, Miller VM. Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases. Alzheimers Res Ther. 2009; 1: 5.
3. Forman MS, Trojanowski JQ, Lee VM. TDP-43: a novel neurodegenerative proteinopathy. Curr Opin Neurobiol. 2007; 17: 548-55.
4. McMillan PJ, Leverenz JB. From model system to clinical medicine: pathophysiologic links of common proteinopathies. Alzheimers Res Ther. 2010; 2: 26.
5. Wakabayashi K, Mori F, Tanji K, et al. Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain. Acta Neuropathol. 2010; 120: 1-12.
6. Kong XC, Bao XQ, Liu GT. [Neurodegenerative conformational disease and heat shock proteins]. Yao Xue Xue Bao. 2010; 45: 1333-8.
7. Galpern WR, Lang AE. Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol. 2006; 59: 449-58.
8. Mandal PK, Pettegrew JW, Masliah E, et al. Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem Res. 2006; 31: 1153-62.
9. Jellinger KA. Basic mechanisms of neurodegeneration: a critical update. J Cell Mol Med. 2010; 14: 457-87.
10. Kovacs GG, Botond G, Budka H. Protein coding of neurodegenerative dementias: the neuropathological basis of biomarker diagnostics. Acta Neuropathol. 2010; 119: 389-408.
11. Reiniger L, Lukic A, Linehan J, et al. Tau, prions and Abeta: the triad of neurodegeneration. Acta Neuropathol. 2011; 121: 5-20.
12. Dickson DW. Introduction. In: Weller RO, editor. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Oxford: Wiley-Blackwell: 2011. p. 3-5.
13. Jellinger KA. Interaction between a-synuclein and other proteins in neurodegenerative disorders. Sci World J. 2011; 11: 1893-907.
14. Powers ET, Morimoto RI, Dillin A, et al. Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem. 2009; 78: 959-91.
15. Naiki H, Nagai Y. Molecular pathogenesis of protein misfolding diseases: pathological molecular environments versus quality control systems against misfolded proteins. J Biochem. 2009; 146: 751-6.
16. Filosto M, Scarpelli M, Cotelli MS, et al. The role of mitochondria in neurodegenerative diseases. J Neurol. 2011; 258: 1763-74.
17. Schon EA, Przedborski S, Crews L. Mitochondria: the next (neurode)generation. Neuron. 2011; 70: 1033-53.
18. Schulz-Schaeffer WJ. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol. 2010; 120: 131-43.
19. Takahashi RH, Capetillo-Zarate E, Lin MT, et al. Co-occurrence of Alzheimer's disease abeta-amyloid and tau pathologies at synapses. Neurobiol Aging 2010; 31: 1145-52.
20. Lansbury PT, Lashuel HA. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 2006; 443: 774-9.
21. Glabe CG. Structural classification of toxic amyloid oligomers. J Biol Chem. 2008; 283: 29639-43.
22. Hamaguchi T, Eisele YS, Varvel NH, et al. The presence of Abeta seeds, and not age per se, is critical to the initiation of Abeta deposition in the brain. Acta Neuropathol. 2011; in press: doi: 10.1007/s00401-011-0912-1.
23. Gadad BS, Britton GB, Rao KS. Targeting oligomers in neurodegenerative disorders: lessons from alpha-synuclein, tau, and amyloid-beta peptide. J Alzheimers Dis. 2011; 24: 223-32.
24. Patterson KR, Remmers C, Fu Y, et al. Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J Biol Chem. 2011; 286: 23063-76.
25. Tsigelny IF, Crews L, Desplats P, et al. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS ONE 2008; 3: e3135.
26. Olivares D, Huang X, Branden L, et al. Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element. Int J Mol Sci. 2009; 10: 1226-60.
27. Kostka M, Hogen T, Danzer KM, et al. Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. J Biol Chem. 2008; 283: 10992-1003.
28. Levin J, Högen T, Hillmer AS, et al. Generation of ferric iron links oxidative stress to alpha-synuclein oligomer formation. J Parkinson Dis. 2011; 1: 205-16.
29. Putcha P, Danzer KM, Kranich LR, et al. Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity. J Pharmacol Exp Ther. 2010; 332: 849-57.
30. Uversky VN. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J Neurochem. 2007; 103: 17-37.
31. Spillantini MG. Introduction to alpha-synucleinopathies. In: Dickson DW, Weller RO, editors. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, 2nd ed. Oxford: Blackwell Publishing Ltd.; 2011. p. 191-3.
32. Chen L, Periquet M, Wang X, et al. Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest. 2009; 119: 3257-65.
33. Paleologou KE, Kragh CL, Mann DM, et al. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 2009; 132: 1093-101.
34. Lee SJ, Desplats P, Sigurdson C, et al. Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol. 2010; 6: 702-6.
35. Volpicelli-Daley LA, Luk KC, Patel TP, et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011; 72: 57-71.
36. Winner B, Jappelli R, Maji SK, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA 2011; 108: 4194-9.
37. Danzer KM, Krebs SK, Wolff M, et al. Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology. J Neurochem. 2009; 111: 192-203.
38. Steiner JA, Angot E, Brundin P. A deadly spread: cellular mechanisms of alpha-synuclein transfer. Cell Death Differ. 2011; 18: 1425-33.
39. Hilker R, Brotchie JM, Chapman J. Pros and cons of a prion-like pathogenesis in Parkinson's disease. BMC Neurol. 2011; 11: 74.
40. Spires-Jones TL, Meyer-Luehmann M, Osetek JD, et al. Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. Am J Pathol. 2007; 171: 1304-11.
41. Kuchibhotla KV, Goldman ST, Lattarulo CR, et al. Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 2008; 59: 214-25.
42. Wu HY, Hudry E, Hashimoto T, et al. Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J Neurosci. 2010; 30: 2636-49.
43. Crouch PJ, Harding SM, White AR, et al. Mechanisms of Abeta mediated neurodegeneration in Alzheimer's disease. Int J Biochem Cell Biol. 2008; 40: 181-98.
44. Fox LM, William CM, Adamowicz DH, et al. Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model. J Neuropathol Exp Neurol. 2011; 70: 588-95.
45. Nygaard HB, Strittmatter SM. Cellular prion protein mediates the toxicity of beta-amyloid oligomers: implications for Alzheimer disease. Arch Neurol. 2009; 66: 1325-8.
46. Chen S, Yadav SP, Surewicz WK. Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role of N-terminal residues. J Biol Chem. 2010; 285: 26377-83.
47. Zou WQ, Xiao X, Yuan J, et al. Amyloid-beta42 interacts mainly with insoluble prion protein in the Alzheimer brain. J Biol Chem. 2011; 286: 15095-105.
48. Forloni G, Balducci C. Beta-amyloid oligomers and prion protein: fatal attraction? Prion 2011; 5: 10-5.
49. Gunther EC, Strittmatter SM. Beta-amyloid oligomers and cellular prion protein in Alzheimer's disease. J Mol Med. 2010; 88: 331-8.
50. Lauren J, Gimbel DA, Nygaard HB, et al. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009; 457: 1128-32.
51. Hanger DP, Noble W. Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation. Int J Alzheimers Dis. 2011; 2011: 352805.
52. Engel T, Goni-Oliver P, Lucas JJ, et al. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem. 2006; 99: 1445-55.
53. Alonso AC, Li B, Grundke-Iqbal I, et al. Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies. Curr Alzheimer Res. 2008; 5: 375-84.
54. Lucas JJ, Hernandez F, Gomez-Ramos P, et al. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 2001; 20: 27-39.
55. de Calignon A, Fox LM, Pitstick R, et al. Caspase activation precedes and leads to tangles. Nature 2010; 464: 1201-4.
56. Guo JL, Lee VM. Seeding of normal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem. 2011; 286: 15317-31.
57. Kwong LK, Uryu K, Trojanowski JQ, et al. TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis. Neurosignals 2008; 16: 41-51.
58. Wilson AC, Dugger BN, Dickson DW, et al.TDP-43 in aging and Alzheimer's disease - a review. Int J Clin Exp Pathol. 2011; 4: 147-55.
59. Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010; 9: 995-1007.
60. Lanson NA Jr, Maltare A, King H, et al. A Drosophila model of FUS-related neurodegeneration reveals genetic interaction between FUS and TDP-43. Hum Mol Genet. 2011; 20: 2510-23.
61. Serrano-Pozo A, Frosch MP, Masliah E, et al. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011; 1: a006189.
62. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010; 362: 329-44.
63. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995; 16: 271-8.
64. DaRocha-Souto B, Scotton TC, Coma M, et al. Brain oligomeric beta-amyloid but not total amyloid plaque burden correlates with neuronal loss and astrocyte inflammatory response in amyloid precursor protein/tau transgenic mice. J Neuropathol Exp Neurol. 2011; 70: 360-76.
65. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002; 298: 789-91.
66. Scheff SW, Price DA, Schmitt FA, et al. Synaptic loss in the inferior temporal gyrus in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis. 2011; 24: 547-57.
67. Hardy J. The relationship between amyloid and tau. J Mol Neurosci. 2003; 20: 203-6.
68. Rhein V, Eckert A. Effects of Alzheimer's amyloid-beta and tau protein on mitochondrial function - role of glucose metabolism and insulin signalling. Arch Physiol Biochem. 2007; 113: 131-41.
69. Gotz J, Lim YA, Ke YD, et al. Dissecting toxicity of tau and beta-amyloid. Neurodegener Dis. 2010; 7: 10-2.
70. Ittner LM, Gotz J. Amyloid-beta and tau - a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci. 2011; 12: 65-72.
71. Huang HC, Jiang ZF. Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease. J Alzheimers Dis. 2009; 16: 15-27.
72. Ferrer I, Barrachina M, Puig B. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol. 2002; 104: 583-91.
73. Ferrer I, Gomez-Isla T, Puig B, et al. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res. 2005; 2: 3-18.
74. Baum L, Seger R, Woodgett JR, et al. Overexpressed tau protein in cultured cells is phosphorylated without formation of PHF: implication of phosphoprotein phosphatase involvement. Brain Res Mol Brain Res. 1995; 34: 1-17.
75. Leroy A, Landrieu I, Huvent I, et al. Spectroscopic studies of GSK3β phosphorylation of the neuronal tau protein and its interaction with the N-terminal domain of apolipoprotein E. J Biol Chem. 2010; 285: 33435-44.
76. Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J Neurochem. 2008; 104: 1433-9.
77. Hernandez F, Gomez de Barreda E, Fuster-Matanzo A, et al. GSK3: a possible link between beta amyloid peptide and tau protein. Exp Neurol. 2010; 223: 322-5.
78. Proctor CJ, Gray DA. GSK3 and p53 - is there a link in Alzheimer's disease? Mol Neurodegener. 2010; 5: 7.
79. Shin RW, Ogino K, Shimabuku A, et al. Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Abeta and tau. Acta Neuropathol. 2007; 113: 627-36.
80. Fein JA, Sokolow S, Miller CA, et al. Co-localization of amyloid beta and tau pathology in Alzheimer's disease synaptosomes. Am J Pathol. 2008; 172: 1683-92.
81. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
82. Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. J Clin Invest. 2005; 115: 1449-57.
83. Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med. 2011; 3: 89ra57.
84. Eisele YS, Bolmont T, Heikenwalder M, et al. Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci USA. 2009; 106: 12926-31.
85. Eisele YS, Obermuller U, Heilbronner G, et al. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 2010; 330: 980-2.
86. Langer F, Eisele YS, Fritschi SK, et al. Soluble Aβ seeds are potent inducers of cerebral β-amyloid deposition. J Neurosci. 2011; 31: 14488-95.
87. Rosen RF, Fritz JJ, Dooyema J, et al. Exogenous seeding of cerebral beta-amyloid deposition in betaAPP-transgenic rats. J Neurochem. 2011; in press: doi: 10.1111/j.1471-4159.2011.07551.x.
88. Sutcliffe EL, Bunting KL, He YQ, et al. Chromatin-associated protein kinase C-theta regulates an inducible gene expression program and microRNAs in human T lymphocytes. Mol Cell. 2011; 41: 704-19.
89. Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med. 2011; 3: 77sr1.
90. Lesne S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006; 440: 352-7.
91. Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998; 95: 6448-53.
92. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008; 14: 837-42.
93. Jin M, Shepardson N, Yang T, et al. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci USA. 2011; 108: 5819-24.
94. Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007; 316: 750-4.
95. Small DH, Mok SS, Bornstein JC. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci. 2001; 2: 595-8.
96. Gotz J, Streffer JR, David D, et al. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol Psychiatry. 2004; 9: 664-83.
97. De Felice FG, Wu D, Lambert MP, et al. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Abeta oligomers. Neurobiol Aging. 2008; 29: 1334-47.
98. Bolmont T, Clavaguera F, Meyer-Luehmann M, et al. Induction of tau pathology by intracerebral infusion of amyloid-beta-containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am J Pathol. 2007; 171: 2012-20.
99. Ittner LM, Ke YD, Delerue F, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell. 2010; 142: 387-97.
100. Gotz J, Chen F, van Dorpe J, et al. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001; 293: 1491-5.
101. Folwell J, Cowan CM, Ubhi KK, et al. Abeta exacerbates the neuronal dysfunction caused by human tau expression in a Drosophila model of Alzheimer's disease. Exp Neurol. 2010; 223: 401-9.
102. Sofola O, Kerr F, Rogers I, et al. Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease. PLoS Genet. 2010; 6: e1001087. doi:10.1371/journal.pgen.1001087.
103. Cowan CM, Sealey MA, Quraishe S, et al. Modelling tauopathies in Drosophila: insights from the fruit fly. Int J Alzheimers Dis. 2011; in press.
104. Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003; 39: 409-21.
105. Hurtado DE, Molina-Porcel L, Iba M, et al. Aβ accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am J Pathol. 2010; 177: 1977-88.
106. Green KN, Billings LM, Roozendaal B, et al. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J Neurosci. 2006; 26: 9047-56.
107. Billings LM, Oddo S, Green KN, et al. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005; 45: 675-88.
108. Gong EJ, Park HR, Kim ME, et al. Morin attenuates tau hyperphosphorylation by inhibiting GSK3beta. Neurobiol Dis. 2011; 44, 223-30.
109. Coomaraswamy J, Kilger E, Wolfing H, et al. Modeling familial Danish dementia in mice supports the concept of the amyloid hypothesis of Alzheimer's disease. Proc Natl Acad Sci USA. 2010; 107: 7969-74.
110. Winton MJ, Lee EB, Sun E, et al. Intraneuronal APP, not free Abeta peptides in 3xTg-AD mice: implications for tau versus Abeta-mediated Alzheimer neurodegeneration. J Neurosci. 2011; 31: 7691-9.
111. Wirths O, Dins A, Bayer TA. AbetaPP accumulation and/or intraneuronal Abeta accumulation? The 3xTg-AD mouse model revisited. J Alzheimers Dis. 2011 in press: doi: 10.3233/JAD-2011-111529.
112. Nakayama K, Ohkawara T, Hiratochi M, et al. The intracellular domain of amyloid precursor protein induces neuron-specific apoptosis. Neurosci Lett. 2008; 444: 127-31.
113. Ohkawara T, Nagase H, Koh CS, et al. The amyloid precursor protein intracellular domain alters gene expression and induces neuron-specific apoptosis. Gene. 2011; 475: 1-9.
114. Hunter JM, Bowers WJ, Maarouf CL, et al. Biochemical and morphological characterization of the AbetaPP/PS/Tau TRIPLE transgenic mouse model and its relevance to sporadic Alzheimer's disease. J Alzheimers Dis. 2011; 27: 361-76.
115. Rhein V, Song X, Wiesner A, et al. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci USA 2009; 106: 20057-62.
116. Eckert A, Schmitt K, Gotz J. Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-beta toxicity. Alzheimers Res Ther. 2011; 3: 15.
117. Eckert A, Schulz KL, Rhein V, et al. Convergence of amyloid-beta and tau pathologies on mitochondria in vivo. Mol Neurobiol. 2010; 41: 107-14.
118. Rajendran L, Honsho M, Zahn TR, et al. Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci USA 2006; 103: 11172-7.
119. Vossel KA, Zhang K, Brodbeck J, et al. Tau reduction prevents Abeta-induced defects in axonal transport. Science 2010; 330: 198.
120. Saper CB, Wainer BH, German DC. Axonal and transneuronal transport in the transmission of neurological disease: potential role in system degenerations, including Alzheimer's disease. Neuroscience 1987; 23: 389-98.
121. Stamer K, Vogel R, Thies E, et al. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol. 2002; 156: 1051-63.
122. Pappolla MA, Omar RA, Kim KS, et al. Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease. Am J Pathol. 1992; 140: 621-8.
123. Perez JL, Carrero I, Gonzalo P, et al. Soluble oligomeric forms of beta-amyloid (Abeta) peptide stimulate Abeta production via astrogliosis in the rat brain. Exp Neurol. 2010; 223: 410-21.
124. Novak P, Prcina M, Kontsekova E. Tauons and prions: infamous cousins? J Alzheimers Dis. 2011; 26: 413-30.
125. Guo JP, Arai T, Miklossy J, et al. Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc Natl Acad Sci USA 2006; 103: 1953-8.
126. Miller Y, Ma B, Nussinov R. Synergistic interactions between repeats in tau protein and Abeta amyloids may be responsible for accelerated aggregation via polymorphic states. Biochemistry 2011; 50: 5172-81.
127. Yoshiyama Y, Higuchi M, Zhang B, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007; 53: 337-51.
128. Rocher AB, Crimins JL, Amatrudo JM, et al. Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs. Exp Neurol. 2010; 223: 385-93.
129. Braak H, Thal DR, Ghebremedhin E, et al. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011; 70: 960-9.
130. Thal DR, Rub U, Orantes M, et al. Phases of Abeta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-800.
131. Thal DR, Capetillo-Zarate E, Del Tredici K, et al. The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowledge Environ. 2006; 2006: re1.
132. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005; 25: 7709-17.
133. Walker LC, Jucker M. Amyloid by default. Nat Neurosci. 2011; 14: 669-70.
134. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82: 239-59.
135. Alafuzoff I, Arzberger T, Al-Sarraj S, et al. Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol. 2008; 18: 484-96.
136. Braak H, Del Tredici K. Alzheimer's pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathol. 2011; 121: 589-95.
137. Braak H, Del Tredici K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol. 2011; 121: 171-81.
138. Simic G, Stanic G, Mladinov M, et al. Does Alzheimer's disease begin in the brainstem? Neuropathol Appl Neurobiol. 2009; 35: 532-54.
139. Grinberg LT, Rub U, Ferretti RE, et al. The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset?. Neuropathol Appl Neurobiol. 2009; 35: 406-16.
140. Elobeid A, Soininen H, Alafuzoff I. Hyperphosphorylated tau in young and middle-aged subjects. Acta Neuropathol. 2011; in press: doi: 10.1007/s00401-011-0897-9.
141. Postupna N, Rose SE, Bird TD, et al. Novel antibody capture assay for paraffin-embedded tissue detects wide-ranging amyloid beta and paired helical filament-tau accumulation in cognitively normal older adults. Brain Pathol. 2011; in press: doi: 10.1111/j.1750-3639.2011.00542.x.
142. Desikan RS, McEvoy LK, Thompson WK, et al. Amyloid-beta associated volume loss occurs only in the presence of phospho-tau. Ann Neurol. 2011; 70: 657-61.
143. Avila J. Alzheimer disease: caspases first. Nat Rev Neurol. 2010; 6: 587-8.
144. Iqbal K, Grundke-Iqbal I. Opportunities and challenges in developing Alzheimer disease therapeutics. Acta Neuropathol. 2011; 122: 543-9.
145. Irvine GB, El-Agnaf OM, Shankar GM, et al. Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol Med. 2008; 14: 451-64.
146. Higashi S, Iseki E, Yamamoto R, et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Res. 2007; 1184: 284-94.
147. Iseki E, Togo T, Suzuki K, et al. Dementia with Lewy bodies from the perspective of tauopathy. Acta Neuropathol. 2003; 105: 265-70.
148. Miklossy J, Steele JC, Yu S, et al. Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC). Acta Neuropathol. 2008; in press: 116: 625-37.
149. Leverenz JB, Umar I, Wang Q, et al. Proteomic identification of novel proteins in cortical Lewy bodies. Brain Pathol. 2007; 17: 139-45.
150. Burns SA, Moran CR, Pingerelli PL, et al. Redefining the Lewy body: evidence of distinct protein composition and nonrandon assembly process (abstr.). Mov Disord. 2008; 23(Suppl 1): S22.
151. van Dijk KD, Berendse HW, Drukarch B, et al. The proteome of the locus ceruleus in Parkinson's disease: relevance to pathogenesis. Brain Pathol. 2011; in press: doi: 10.1111/j.1750-3639.2011.00540.x.
152. Goris A, Williams-Gray CH, Clark GR, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol. 2007; 62: 145-53.
153. Strobel G. The spectrum series: grappling with the overlap between Alzheimer's and Parkinson's diseases. 9th International Conference on Alzheimer's and Parkinson's Diseases, 11-15 March 2009, Prague, Czech Republic. J Alzheimers Dis. 2009; 18: 625-40.
154. Arai Y, Yamazaki M, Mori O, et al. Alpha-synuclein-positive structures in cases with sporadic Alzheimer's disease: morphology and its relationship to tau aggregation. Brain Res. 2001; 888: 287-96.
155. Duda JE, Giasson BI, Mabon ME, et al. Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol. 2002; 104: 7-11.
156. Badiola N, de Oliveira RM, Herrera F, et al. Tau enhances alpha-synuclein aggregation and toxicity in cellular models of synucleinopathy. PLoS ONE 2011; 6: e26609.
157. Maries E, Dass B, Collier TJ, et al. The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci. 2003; 4: 727-38.
158. Badiola N, Suarez-Calvet M, Lleo A. Tau phosphorylation and aggregation as a therapeutic target in tauopathies. CNS Neurol Disord Drug Targets. 2010; 9: 727-40.
159. Waxman EA, Giasson BI. Induction of intracellular tau aggregation is promoted by alpha-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J Neurosci. 2011; 31: 7604-18.
160. Nonaka T, Watanabe ST, Iwatsubo T, et al. Seeded aggregation and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative diseases. J Biol Chem. 2010; 285: 34885-98.
161. Duka T, Duka V, Joyce JN, et al. Alpha-synuclein contributes to GSK-3beta-catalyzed tau phosphorylation in Parkinson's disease models. FASEB J. 2009; 23: 2820-30.
162. Wills J, Credle J, Haggerty T, et al. Tauopathic changes in the striatum of A53T alpha-synuclein mutant mouse model of Parkinson's disease. PLoS ONE 2011; 6: e17953.
163. Kaul T, Credle J, Haggerty T, et al. Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson's disease. BMC Neurosci. 2011; 12: 79.
164. Haggerty T, Credle J, Rodriguez O, et al. Hyperphosphorylated tau in an alpha-synuclein-overexpressing transgenic model of Parkinson's disease. Eur J Neurosci. 2011; 33: 1598-610.
165. Qureshi HY, Paudel HK. Parkinsonian neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) and α-synuclein mutations promote tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitro. J Biol Chem. 2011; 286: 5055-68.
166. Riedel M, Goldbaum O, Richter-Landsberg C. Alpha-synuclein promotes the recruitment of tau to protein inclusions in oligodendroglial cells: effects of oxidative and proteolytic stress. J Mol Neurosci. 2009; 39: 226-34.
167. Chaves RS, Melo TQ, Martins SA, et al. Protein aggregation containing beta-amyloid, alpha-synuclein and hyperphosphorylated tau in cultured cells of hippocampus, substantia nigra and locus coeruleus after rotenone exposure. BMC Neurosci. 2010; 11: 144.
168. Lei P, Ayton S, Finkelstein DI, et al. Tau protein: relevance to Parkinson's disease. Int J Biochem Cell Biol. 2010; 42: 1775-8.
169. Emmer KL, Waxman EA, Covy JP, et al. E46K human {alpha}-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent detrimental motor impairments. J Biol Chem. 2011; 286: 35104-8.
170. Wills J, Jones J, Haggerty T, et al. Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol. 2010; 225: 210-8.
171. Esposito A, Dohm CP, Kermer P, et al. Alpha-synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton. Neurobiol Dis. 2007; 26: 521-31.
172. Kawakami F, Suzuki M, Shimada N, et al. Stimulatory effect of alpha-synuclein on the tau-phosphorylation by GSK-3beta. FEBS J. 2011; 278: 4895-904.
173. Lebel M, Patenaude C, Allyson J, et al. Dopamine D1 receptor activation induces tau phosphorylation via cdk5 and GSK3 signaling pathways. Neuropharmacology 2009; 57: 392-402.
174. McNaught KS, Belizaire R, Jenner P, et al. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett. 2002; 326: 155-8.
175. Duka T, Rusnak M, Drolet RE, et al. Alpha-synuclein induces hyperphosphorylation of tau in the MPTP model of parkinsonism. FASEB J. 2006; 20: 2302-12.
176. Duka T, Sidhu A. The neurotoxin, MPP+, induces hyperphosphorylation of tau, in the presence of alpha-synuclein, in SH-SY5Y neuroblastoma cells. Neurotox Res. 2006; 10: 1-10.
177. Kozikowski AP, Gaisina IN, Petukhov PA, et al. Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease. Chem Med Chem. 2006; 1: 256-66.
178. van Eersel J, Bi M, Ke YD, et al. Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains. J Neural Transm. 2009; 116: 1243-51.
179. Uchihara T, Hara M, Nakamura A, et al. Tangle evolution differentiated by three- and four-repeat tau. Double immunofluorolabeling study with two monoclonal antibodies. Histochem Cell Biol. 2011; in press: doi: 10.1007/s00418-011-0891-2.
180. Giasson BI, Forman MS, Higuchi M, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science. 2003; 300: 636-40.
181. Kotzbauer PT, Giasson BI, Kravitz AV, et al. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. Exp Neurol. 2004; 187: 279-88.
182. Morales R, Estrada LD, Diaz-Espinoza R, et al. Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases. J Neurosci. 2010; 30: 4528-35.
183. Seto-Salvia N, Clarimon J, Pagonabarraga J, et al. Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch Neurol. 2011; 68: 359-64.
184. Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009; 41: 1308-12.
185. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009; 132: 2958-69.
186. Wray S, Lewis PA. A tangled web - tau and sporadic Parkinson's disease. Front Psychiatry 2010; 1: 150.
187. Clarimon J, Molina-Porcel L, Gomez-Isla T, et al. Early-onset familial Lewy body dementia with extensive tauopathy: a clinical, genetic, and neuropathological study. J Neuropathol Exp Neurol. 2009; 68: 73-82.
188. Peuralinna T, Oinas M, Polvikoski T, et al. Neurofibrillary tau pathology modulated by genetic variation of alpha-synuclein. Ann Neurol. 2008; 64: 348-52.
189. Muntane G, Dalfo E, Martinez A, et al. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies. Neuroscience 2008; 152: 913-23.
190. Frasier M, Walzer M, McCarthy L, et al. Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein. Exp Neurol. 2005; 192: 274-87.
191. Fujishiro H, Tsuboi Y, Lin WL, et al. Co-localization of tau and alpha-synuclein in the olfactory bulb in Alzheimer's disease with amygdala Lewy bodies. Acta Neuropathol. 2008; 116: 17-24.
192. Shao CY, Crary JF, Rao C, et al. Atypical protein kinase C in neurodegenerative disease II: PKCiota/lambda in tauopathies and alpha-synucleinopathies. J Neuropathol Exp Neurol. 2006; 65: 327-35.
193. Ishizawa T, Mattila P, Davies P, et al. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol. 2003; 62: 389-97.
194. Piao YS, Hayashi S, Hasegawa M, et al. Co-localization of alpha-synuclein and phosphorylated tau in neuronal and glial cytoplasmic inclusions in a patient with multiple system atrophy of long duration. Acta Neuropathol. 2001; 101: 285-93.
195. Nagaishi M, Yokoo H, Nakazato Y. Tau-positive glial cytoplasmic granules in multiple system atrophy. Neuropathology 2011; 31: 299-305.
196. Dickson DW. Alpha-synuclein and the Lewy body disorders. Curr Opin Neurol. 2001; 14: 423-32.
197. Trembath Y, Rosenberg C, Ervin JF, et al. Lewy body pathology is a frequent co-pathology in familial Alzheimer's disease. Acta Neuropathol. 2003; 105: 484-8.
198. Uchikado H, Lin WL, DeLucia MW, et al. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol. 2006; 65: 685-97.
199. Attems J, Quass M, Jellinger KA. Tau and alpha-synuclein brainstem pathology in Alzheimer disease: relation with extrapyramidal signs. Acta Neuropathol. 2007; 113: 53-62.
200. Burns JM, Galvin JE, Roe CM, et al. The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs. Neurology 2005; 64: 1397-403.
201. Liu Y, Stern Y, Chun MR, et al. Pathological correlates of extrapyramidal signs in Alzheimer's disease. Ann Neurol. 1997; 41: 368-74.
202. Nakashima-Yasuda H, Uryu K, Robinson J, et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol. 2007; 114: 221-9.
203. Arai T, Mackenzie IR, Hasegawa M, et al. Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol. 2009; 117: 125-36.
204. Saito Y, Ruberu NN, Sawabe M, et al. Lewy body-related alpha-synucleinopathy in aging. J Neuropathol Exp Neurol. 2004; 63: 742-9.
205. Jellinger K. Unusual tau in MSA. Neuropathology. 2011; in press: doi: 10.1111/j.440-789.2011.01246.x.
206. Jellinger KA. Interaction between alpha-synuclein and tau in Parkinson's disease. Comment on Wills, et al.: Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 2010; 225: 210-218.
207. Lee VM, Giasson BI, Trojanowski JQ. More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. Trends Neurosci. 2004; 27: 129-34.
208. Obi K, Akiyama H, Kondo H, et al. Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies. Exp Neurol. 2008; 210: 409-20.
209. Lee SJ, Lim HS, Masliah E, et al. Protein aggregate spreading in neurodegenerative diseases: problems and perspectives. Neurosci Res. 2011; 70: 339-48.
210. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al. Alpha-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011; 10: 230-40.
211. Parnetti L, Chiasserini D, Bellomo G, et al. Cerebrospinal fluid tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord. 2011; 26: 1428-35.
212. Mulugeta E, Londos E, Hansson O, et al. Cerebrospinal fluid levels of sAPPalpha and sAPPbeta in Lewy body and Alzheimer's disease: clinical and neurochemical correlates. Int J Alzheimers Dis. 2011; 2011: 495025.
213. Pletnikova O, West N, Lee MK, et al. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 2005; 26: 1183-92.
214. Lashley T, Holton JL, Gray E, et al. Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol. 2008; 115: 417-25.
215. Masliah E, Rockenstein E, Veinbergs I, et al. Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA. 2001; 98: 12245-50.
216. Bate C, Gentleman S, Williams A. Alpha-synuclein induced synapse damage is enhanced by amyloid-beta1-42. Mol Neurodegener. 2010; 5: 55.
217. Small SA, Duff K. Linking Abeta and tau in late-onset Al.zheimer's disease: a dual pathway hypothesis. Neuron 2008; 60: 534-42.
218. Fjorback AW, Sundbye S, Dachsel JC, et al. P25alpha/TPPP expression increases plasma membrane presentation of the dopamine transporter and enhances cellular sensitivity to dopamine toxicity. FEBS J. 2011; 278: 493-505.
219. Olah J, Vincze O, Virok D, et al. Interactions of pathological hallmark proteins: tubulin polymerization promoting protein/p25, β-amyloid and α-synuclein. J Biol Chem. 2011; 286: 34088-100.
220. Kovacs GG, Laszlo L, Kovacs J, et al. Natively unfolded tubulin polymerization promoting protein TPPP/p25 is a common marker of alpha-synucleinopathies. Neurobiol Dis. 2004; 17: 155-62.
221. Kragh CL, Lund LB, Febbraro F, et al. α-synuclein aggregation and ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J Biol Chem. 2009; 284: 10211-22.
222. Hasegawa T, Baba T, Kobayashi M, et al. Role of TPPP/p25 on alpha-synuclein-mediated oligodendroglial degeneration and the protective effect of SIRT2 inhibition in a cellular model of multiple system atrophy. Neurochem Int. 2010; 57: 857-66.
223. Luk KC, Song C, O'Brien P, et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci USA 2009; 106: 20051-6.
224. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006; 313: 1781-4.
225. Lee HJ, Patel S, Lee SJ. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci. 2005; 25: 6016-24.
226. Clavaguera F, Bolmont T, Crowther RA, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009; 11: 909-13.
227. Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA 2009; 106: 13010-5.
228. Ren PH, Lauckner JE, Kachirskaia I, et al. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol. 2009; 11: 219-25.
229. Mendez I, Vinuela A, Astradsson A, et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med. 2008; 14: 507-9.
230. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
231. Braak H, Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv Anat Embryol Cell Biol. 2009; 201: 1-119.
232. Braak H, Del Tredici K. [Pathophysiology of sporadic Parkinson's disease]. Fortschr Neurol Psychiatr. 2010; 78: S2-4.
233. Parkkinen L, Pirttila T, Alafuzoff I. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol. 2008; 115: 399-407.
234. Kalaitzakis ME, Graeber MB, Gentleman SM, et al. Controversies over the staging of alpha-synuclein pathology in Parkinson's disease. Acta Neuropathol. 2008; 116: 125-8.
235. Jellinger KA. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta 2009; 1792: 730-40.
236. Dickson DW, Uchikado H, Fujishiro H, et al. Evidence in favor of Braak staging of Parkinson's disease. Mov Disord. 2010; 25: S78-82.
237. Kordower JH, Chu Y, Hauser RA, et al. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord. 2008; 23: 2303-6.
238. Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med. 2008; 14: 501-3.
239. Brundin P, Li JY, Holton JL, et al. Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci. 2008; 9: 741-5.
240. Li JY, Englund E, Widner H, et al. Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov Disord. 2010; 25: 1091-6.
241. Hansen C, Angot E, Bergstrom AL, et al. Alpha-synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest. 2011; 121: 715-25.
242. Lee HJ, Suk JE, Bae EJ, et al. Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol. 2008; 40: 1835-49.
243. Kordower JH, Dodiya HB, Kordower AM, et al. Transfer of host-derived alpha synuclein to grafted dopaminergic neurons in rat. Neurobiol Dis. 2011; 43: 552-7.
244. Aguzzi A, Rajendran L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron 2009; 64: 783-90.
245. Angot E, Steiner JA, Hansen C, et al. Are synucleinopathies prion-like disorders? Lancet Neurol. 2010; 9: 1128-38.
246. Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol. 2010; 11: 301-7.
247. Goedert M, Clavaguera F, Tolnay M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci. 2010; 33: 317-25.
248. Resenberger UK, Harmeier A, Woerner AC, et al. The cellular prion protein mediates neurotoxic signalling of beta-sheet-rich conformers independent of prion replication. EMBO J. 2011; 30: 2057-70.
249. Sandberg MK, Al-Doujaily H, Sharps B, et al. Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature 2011; 470: 540-2.
250. Chia R, Tattum MH, Jones S, et al. Superoxide dismutase 1 and tgSOD1 mouse spinal cord seed fibrils, suggesting a propagative cell death mechanism in amyotrophic lateral sclerosis. PLoS ONE. 2010; 5: e10627.
251. Munch C, O'Brien J, Bertolotti A. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc Natl Acad Sci USA 2011; 108: 3548-53.
252. Furukawa Y, Kaneko K, Watanabe S, et al. A seeding reaction recapitulates intracellular formation of Sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions. J Biol Chem. 2011; 286: 18664-72.
253. Mackenzie IR, Neumann M, Baborie A, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011; 122: 111-3.
254. Novak M. Truncated tau protein as a new marker for Alzheimer's disease. Acta Virol. 1994; 38: 173-89.
255. Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009; 284: 12845-52.
256. Frost B, Ollesch J, Wille H, et al. Conformational diversity of wild-type tau fibrils specified by templated conformation change. J Biol Chem. 2009; 284: 3546-51.
257. Brown P, Brandel JP, Preece M, et al. Iatrogenic Creutzfeldt-Jakob disease: the waning of an era. Neurology. 2006; 67: 389-93.
258. Brown P. Transmissible spongiform encephalopathy in the 21st century: neuroscience for the clinical neurologist. Neurology. 2008; 70: 713-22.
259. Watt NT, Hooper NM. Prion protein in Alzheimer's disease - Editorial. Future Neurol 2007; 2: 587-90.
260. Freir DB, Nicoll AJ, Klyubin I, et al. Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites. Nat Commun. 2011; 2: 336.
261. Balch WE, Morimoto RI, Dillin A, et al. Adapting proteostasis for disease intervention. Science 2008; 319: 916-9.
262. Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2010; 11: 155-9.
263. Urushitani M, Sik A, Sakurai T, et al. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat Neurosci. 2006; 9: 108-18.
264. Hu WT, Chen-Plotkin A, Arnold SE, et al. Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol. 2010; 120: 385-99.
265. Mollenhauer B, Bibl M, Esselmann H, et al. Tauopathies and synucleinopathies: do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis? J Neural Transm. 2007; 114: 919-27.
266. Hu X, Crick SL, Bu G, et al. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc Natl Acad Sci USA 2009; 106: 20324-9.
267. Sierks MR, Chatterjee G, McGraw C, et al. CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integr Biol. 2011, 3: 1188-96.
268. Bibl M, Mollenhauer B, Esselmann H, et al. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 2006; 129: 1177-87.
269. Aerts MB, Esselink RA, Claassen JA, et al. CSF Tau, Abeta42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease. J Alzheimers Dis. 2011; 27: 377-84.
270. Weick JP, Liu Y, Zhang SC. Human embryonic stem cell-derived neurons adopt and regulate the activity of an established neural network. Proc Natl Acad Sci USA. 2011; 108: 20189-94. doi:.
271. Tomiyama T, Matsuyama S, Iso H, et al. A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci. 2010; 30: 4845-56.
272. Clinton LK, Blurton-Jones M, Myczek K, et al. Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci. 2010; 30: 7281-9.
273. Mrak RE, Griffin WS. Common inflammatory mechanisms in Lewy body disease and Alzheimer disease. J Neuropathol Exp Neurol. 2007; 66: 683-6.
274. Haass C. Initiation and propagation of neurodegeneration. Nat Med. 2010; 16: 1201-4.
275. Kanehisa M, Limviphuvadh V, Tanabe M. Knowledge-based analysis of protein interaction networks in neurodegenerative diseases. In: Alzate O., editor. Neuroproteomics. Boca Raton, FL: CRC Press; 2010. p. 147-62.
276. Silveira JR, Raymond GJ, Hughson AG, et al. The most infectious prion protein particles. Nature 2005; 437: 257-61.
277. Bloch A, Probst A, Bissig H, et al. Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol. 2006; 32: 284-95.
278. Braak H, de Vos RA, Bohl J, et al. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett. 2006; 396: 67-72.
279. Danzer KM, Haasen D, Karow AR, et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci. 2007; 27: 9220-32.
280. Prusiner SB. Prion Biology and Diseases, 2nd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory, 2004.
281. Aguzzi A, O'Connor T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov. 2010; 9: 237-48.
282. Zilka N, Kontsekova E, Novak M. Chaperone-like antibodies targeting misfolded tau protein: new vistas in the immunotherapy of neurodegenerative foldopathies. J Alzheimers Dis. 2008; 15: 169-79.
283. Dennissen FJ, Kholod N, Steinbusch HW, et al. Misframed proteins and neurodegeneration: a novel view on Alzheimer's and Parkinson's diseases. Neurodegener Dis. 2010; 7: 76-9.
284. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res. 2008; 192: 106-13.
285. Malchiodi-Albedi F, Paradisi S, Matteucci A, et al. Amyloid oligomer neurotoxicity, calcium dysregulation, and lipid rafts. Int J Alzheimers Dis. 2011; 2011: 906964.
286. Bartels T, Choi JG, Selkoe DJ. alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature. 2011; 477: 107-10.
287. Canu N, Filesi I, Pristera A, et al. Altered Intracellular Distribution of PrPC and Impairment of Proteasome Activity in Tau Overexpressing Cortical Neurons. J Alzheimers Dis. 2011; 27: 603-13.
288. Osiecka KM, Nieznanska H, Skowronek KJ, et al. Tau inhibits tubulin oligomerization induced by prion protein. Biochim Biophys Acta. 2011; 1813: 1845-53.
289. Jayadev S, Nochlin D, Poorkaj P, et al. Familial prion disease with Alzheimer disease-like tau pathology and clinical phenotype. Ann Neurol. 2011; 69: 712-20.
290. Davidson YS, Raby S, Foulds PG, et al. TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's Syndrome: association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol. 2011; 122: 703-13.
291. Lee EB, Lee VM, Trojanowski JQ. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci. 2011; 13: 38-50.
292. Tomiyama T, Matsuyama S, Iso H, et al. A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci. 2010; 30: 4845-56.
293. Umeda T, Tomiyama T, Sakama N, et al. Intraneuronal amyloid beta oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J Neurosci Res. 2011; 89: 1031-42.
294. Sluchanko NN, Gusev NB. Probable participation of 14-3-3 in tau protein oligomerization and aggregation. J Alzheimers Dis. 2011; 27: 467-76.
295. Lloret A, Badia MC, Giraldo E, et al. Amyloid-beta toxicity and tau hyperphosphorylation are linked via RCAN1 in Alzheimer's disease. J Alzheimers Dis. 2011; 27: 701-9.
296. Amadoro G, Corsetti V, Atlante A, et al. Interaction between NH(2)-tau fragment and Aβ in Alzheimer's disease mitochondria contributes to the synaptic deterioration. Neurobiol Aging. 2011; in press: doi:.
297. Shao CY, Mirra SS, Sait HB, et al. Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Abeta and tau pathology in transgenic mouse models of Alzheimer's disease. Acta Neuropathol. 2011; 122: 285-92.
298. Kopeikina KJ, Carlson GA, Pitstick R, et al. Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain. Am J Pathol. 2011; 179: 2071-82.
299. Karbowski M, Neutzner A, Youle RJ. The mitochondrial E3 ubiquitin ligase MARCH5 is required for Drp1 dependent mitochondrial division. J Cell Biol. 2007; 178: 71-84.
300. Duyckaerts C, Potier MC, Delatour B. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol. 2008; 115: 5-38.
301. Kokjohn TA, Roher AE. Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions. Alzheimers Dement. 2009; 5: 340-7.
302. Christensen DZ, Bayer TA, Wirths O. Intracellular Ass triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer's disease. Neurobiol Aging. 2010; 31: 1153-63.
303. Aho L, Pikkarainen M, Hiltunen M, et al. Immunohistochemical visualization of amyloid-beta protein precursor and amyloid-beta in extra- and intracellular compartments in the human brain. J Alzheimers Dis. 2010; 20: 1015-28.
304. Nakamura K, Nemani VM, Azarbal F, et al. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J Biol Chem. 2011; 286: 20710-26.
305. Yamakawa K, Izumi Y, Takeuchi H, et al. Dopamine facilitates alpha-synuclein oligomerization in human neuroblastoma SH-SY5Y cells. Biochem Biophys Res Commun. 2010; 391: 129-34.
306. Lee HJ, Baek SM, Ho DH, et al. Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers. Exp Mol Med. 2011; 43: 216-22.
307. Pemberton S, Madiona K, Pieri L, et al. Hsc70 protein interaction with soluble and fibrillar alpha-synuclein. J Biol Chem. 2011; 286: 34690-9.
308. Lei P, Ayton S, Bush AI, Adlard PA. GSK-3 in neurodegenerative diseases. Int J Alzheimers Dis. 2011; 2011: 189246.
309. Makarava N, Kovacs GG, Savtchenko R, et al. Genesis of mammalian prions: From non-infectious amyloid fibrils to a transmissible prion disease. PLoS Pathog. 2011; 7: e1002419.
310. Cushman M, Johnson BS, King OD, et al. Prion-like disorders: blurring the divide between transmissibility and infectivity. J Cell Sci. 2010; 123: 1191-201.
311. Takahashi RH, Tobiume M, Sato Y, et al. Accumulation of cellular prion protein within dystrophic neurites of amyloid plaques in the Alzheimer's disease brain. Neuropathology. 2011; 31: 208-14.
312. Moreno-Gonzalez I, Soto C. Misfolded protein aggregates: mechanisms, structures and potential for disease transmission. Semin Cell Dev Biol. 2011; 22: 482-7.
313. Riek R. Cell biology: infectious Alzheimer's disease? Nature. 2006; 444: 429-31.